E
LSL Pharma Group Inc. LSL.V
TSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

09/30/2024 06/30/2024 03/31/2024 12/31/2023 09/30/2023
Revenue 57.01% 102.29% 106.35% 50.68% -7.53%
Total Other Revenue -- -- -- -- --
Total Revenue 57.01% 102.29% 106.35% 50.68% -7.53%
Cost of Revenue 35.37% 94.22% 84.90% -4.99% -25.07%
Gross Profit 151.99% 117.92% 197.10% 108.02% 3,574.00%
SG&A Expenses 54.04% 32.41% -64.75% -91.01% -36.75%
Depreciation & Amortization 4.47% -- -- -- --
Other Operating Expenses -- -- -- -- --
Total Operating Expenses 39.63% 58.55% -9.64% -24.52% -28.66%
Operating Income 133.58% 78.51% 107.49% 105.78% 78.22%
Income Before Tax 50.18% 51.15% 94.80% 84.26% 49.48%
Income Tax Expenses -- -- -- -- --
Earnings from Continuing Operations 50.18% 51.15% 94.80% 84.26% 49.48%
Earnings from Discontinued Operations -- -- -- -- --
Extraordinary Item & Accounting Change -- -- -- -- --
Minority Interest in Earnings -- -- -- -- --
Net Income 50.18% 51.15% 94.80% 84.26% 49.48%
EBIT 133.58% 78.51% 107.49% 105.78% 78.22%
EBITDA 355.65% 155.63% 123.94% 106.81% 110.54%
EPS Basic 63.77% 61.70% 95.61% 86.41% 60.34%
Normalized Basic EPS 57.89% 59.32% 92.02% 86.14% 65.14%
EPS Diluted 66.67% 61.70% 95.61% 86.41% 56.90%
Normalized Diluted EPS 57.89% 59.32% 92.02% 86.14% 65.14%
Average Basic Shares Outstanding 39.60% 28.31% 20.78% 14.74% 27.51%
Average Diluted Shares Outstanding 39.84% 28.46% 20.78% 14.74% 27.51%
Dividend Per Share -- -- -- -- --
Payout Ratio -- -- -- -- --
Weiss Ratings